Publications by authors named "Marie Vanderputten"
Small-cell lung cancer (SCLC) represents 15% of all lung cancers and it is clinically the most aggressive type, being characterized by a tendency for early metastasis, with two-thirds of the patients diagnosed with an extensive stage (ES) disease and a five-year overall survival (OS) as low as 5%. There are still no effective targeted therapies in SCLC despite improved understanding of the molecular steps leading to SCLC development and progression these last years. After four decades, the only modest improvement in OS of patients suffering from ES-SCLC has recently been shown in a trial combining atezolizumab, an anti-PD-L1 immune checkpoint inhibitor, with carboplatin and etoposide, chemotherapy agents.
View Article and Find Full Text PDFArticle Synopsis
- Focal adhesion kinase (FAK) is linked to cancer progression and poor outcomes, but its role in lung cancer specifically is not well understood.
- Researchers analyzed FAK and activated FAK levels in tissue samples from lung cancer patients and healthy controls, finding higher levels in lung cancer tissues overall and even higher in small-cell lung cancer (SCLC) compared to non-small-cell lung cancer (NSCLC).
- Despite these findings, FAK and activated FAK did not show a relation to patient survival or recurrence rates, indicating they may not serve as reliable prognostic markers in lung cancer.